China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB 100 million (USD 13.89 million) in a Series B financing round. The round was led by a fund jointly initiated by AstraZeneca and CICC Capital, with participation from existing investor Ascendum Capital. The proceeds will be used to enhance key infrastructure for novel drugs and medical devices pre-clinical evaluation and to support business development in Hong Kong and beyond.
Infrastructure and Laboratory Network
ZSHK Laboratories boasts independent laboratories in key locations, including the Hong Kong Science and Technology Park, Shenzhen’s Pingshan District in Guangdong Province, and Suzhou Industrial Park in Jiangsu Province. The company has also actively deployed its supply chain, establishing breeding and research bases for experimental dogs and non-human primates in Hunan and Guangxi. These facilities will play a crucial role in supporting the company’s pre-clinical evaluation capabilities and expanding its service offerings.-Fineline Info & Tech
